US-based PerkinElmer has launched a new series of AlphaLISA No Wash immunoassay kits to help enable advanced biomarker research in multiple key disease states, including angiogenesis, inflammation and cancer.
This latest release brings the number of available AlphaLISA assays to 54 kits and is a broad expansion of PerkinElmer’s breakthrough ELISA-alternative ALPHA (Amplified Luminescent Proximity Homogeneous Assay) technology portfolio, the company said.
According to PerkinElmer, AlphaLISA is a powerful proprietary bead-based platform that allows the highly sensitive detection of biomolecules and biomolecular interactions without cumbersome wash steps, enabling researchers to measure very low affinity interactions.
AlphaLISA saves time and eliminates labor-intensive processes that are difficult to automate and it overcomes other traditional limitations of ELISAs, such as assay variation and narrow dynamic range. The technology’s sensitivity and homogeneity also enables savings in precious sample and antibodies usage, the company said.
In addition to angiogenesis, inflammation, and cancer biomarker research assays, the newest AlphaLISA kits feature panels of assays for research in Alzheimer’s, cardiovascular, and metabolic disorders, the company added.
Richard Eglen, president of bio-discovery at PerkinElmer, said: The ability to simplify assays is absolutely critical to laboratory workflow. With compelling advantages over conventional ELISA and other plate-based assays as well as high sensitivity, AlphaLISA provides key advantages in efficiency and discovery in human health research.